Posts

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

on

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

on

Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3

on

Sanofi's Bispecific Lunskeimig Succeeds in Asthma and Sinusitis Phase 2 Trials, Falls Short in Eczema

on

AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway in Skin Diseases

on

Enveda Biosciences Advances ENV-294 to Phase 2 Trials After Promising Phase 1b Data Rivaling Dupixent in Atopic Dermatitis

on

Sanofi Reports Positive but Mixed Phase 3 Results for Amlitelimab in Atopic Dermatitis with OX40L Targeting and Kaposi's Sarcoma Case

on

Apogee Therapeutics' Phase 2 Data Positions Zumilokibart (APG777) as Convenient Alternative to Dupixent and Ebglyss in Eczema Treatment

on

Nektar Therapeutics Reports One-Year Eczema Success with Rezpeg

on

Amgen Ends Autoimmune Alliance with Kyowa Kirin for Rocatinlimab Amid Safety and Efficacy Concerns

on

Sanofi's Amlitelimab Shows Mixed Phase 3 Results in Eczema Trials, Clouds Blockbuster Hopes but Advances to Regulatory Filings

on

Corvus Pharmaceuticals Reports Positive Phase 1 Data for Soquelitinib in Atopic Dermatitis, Exceeding Expectations

on

Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results

on

Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Drug Rocatinlimab

on

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

on

Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations

on

Akeso Scores Two Wins in Phase 3 Trials, Tees Up Regulatory Submissions in China

on

Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical

on

Sanofi Increases Investment in Nurix-Partnership for STAT6 Program

on